Tag: mental health

US could soon approve MDMA therapy — opening an era of psychedelic medicine

For Rick Doblin, 2023 could be a landmark year: the year that the US government decides whether it will allow the use of hallucinogenic drugs to treat mental illness.

Doblin, who is based in Belmont, Massachusetts, is the founder and president of the non-profit organization Multidisciplinary Association for Psychedelic Studies (MAPS). He has spent nearly 40 years researching whether the experience produced by the psychedelic drug MDMA — also called ecstasy or molly — can help people with post-traumatic stress disorder (PTSD). In 2021, MAPS’s phase III clinical trial of 90 people with PTSD found that those who received MDMA coupled with psychotherapy were twice as likely to recover from the condition as were those who received psychotherapy with a placebo1 (see ‘Response to MDMA therapy’).

Keep reading

NEVADA COMMITTEE TO VOTE ON BILL FOR RESEARCH, DECRIMINALIZATION OF PSILOCYBIN

Greg Rea had his first experience with psychedelics when he was 56 years old. Up until then, he’d been a Reno police officer on SWAT for 12 years before retiring from the force to become a pastor and then a real estate investor.

“I retired a couple years ago, but I still was a pretty tightly wound guy,” Rea tells the Weekly in a phone interview. “And I had a seven-days-a-week drinking problem.”

Rea says that despite having a “pretty good life,” like many first responders, alcohol use was adversely affecting him—until about three years ago, when a friend invited him to a group psychedelic experience.

During that experience, which comprised several sessions, a combination of psilocybin [the drug in “magic” mushrooms] and MDMA [aka ecstasy or Molly]took Rea back to two “fairly violent, critical incidents” in which he was involved as a SWAT officer. The intense, emotional trip led to a breakthrough, he says.

“I realized I had some form of PTSD connected to those things,” Rea says. “And I had no idea I’d carried it for almost 20 years.”

After group sessions with other first responders, he began to find a community to talk about mental health—“inner world things” that the wider community might misunderstand. “First responders are exposed to an inordinate amount of human suffering [that] the typical citizen isn’t. So, we said, why don’t we start our own group?”

In the group, firefighters, first responders and current and former military service members are opening up and “finding their healing with psychedelic medicine,” he says. “And I’m free from my seven-days-a-week alcohol habit. My life is just inordinately better. And my relationships are better.”

Rea was one of many who gave public comment during a March 23 hearing for Senate Bill 242 (SB242).

In his testimony, Assemblyman Max Carter said that his therapy with ketamine, the only drug currently legal for psychedelic therapy, has been “transformational” in his mental health and struggle with chronic depression.

“Psilocybin, studies show, is much more powerful. Where I’ve gone through eight or nine ketamine sessions, [it] probably would have been one or two [sessions], if psilocybin was legal,” Carter said, adding that, based on studies, the effects of psilocybin appear to be longer lasting than ketamine.

The bill would establish a framework for research of psilocybin in the state and, if passed as amended, decriminalize possession of the substance, currently listed as a Schedule 1 drug.

Keep reading

In California, Parents May Soon Effectively Lose Custody of Kids 12 and Older 

In California, “stranger danger” may be about to acquire a whole new meaning. 

Forget warning kids. It’s the parents in California who will need to be terrified of strangers if a new bill passes. 

Snuck into AB 665, legislation ostensibly about extending mental health care to lower-income California youths, is a provision that effectively would terminate parents’ rights over their kids as soon as they turn 12. 

The California Family Council warns that this bill “would allow children as young as 12 years old to consent to being placed into state funded group homes without parental permission or knowledge.”  

As long as a mental health professional signs off on it, the kids can go to such a group home—and it doesn’t matter what their parents think. 

“This bill gives a stranger, a school psychologist, power to decide whether a sixth or seventh grader comes home from school that day, and that’s terrifying,” Erin Friday, a California mom of two teens, tells The Daily Signal. 

“This bill is essentially stating that parents are criminals that have to prove their innocence to get their child back,” adds Friday, who is a leader of the parent advocacy group Our Duty. 

Seriously? 

AB 665, which passed out of the Assembly Judiciary Committee last week, builds on a 2010 measure signed into law by then-Gov. Arnold Schwarzenegger, a Republican. That law, the Mental Health Services for At-Risk Youth Act, allowed California children 12 and older to receive mental health care without their parents’ knowledge if a mental health provider determined it was best not to involve the parents.  

That provision was no accident. The Center for American Progress, a liberal think tank, celebrated the California law in a 2010 report as a “useful model for state or federal legislation to address mental illness among LGBT youth.”  

Keep reading

Psychedelics and mental health: Having mystical experiences may yield strongest benefits

It’s a trope seen countless times in books and movies. A character emerges from a drug-induced psychedelic stupor with a fresh outlook and more positive perspective on life. According to new findings from The Ohio State University, however, there may really be some truth to this hallucinogenic notion. Scientists report particularly mystical and insightful psychedelic drug experiences may be associated with an enduring drop in both anxiety and depression symptoms.

Study authors performed a comprehensive machine learning analysis of data pertaining to nearly 1,000 survey respondents who answered questions about their previous non-clinical experiences with psychedelic drugs. Sure enough, those scoring the highest on questionnaires assessing the mystical and insightful nature of their experiences also consistently reported improvements in both depression and anxiety.

Of course, there’s also the risk of encountering a “bad trip.” What happens if a psychedelic experience becomes unpleasant, frightening, or destabilizing? Surprisingly, the study actually found that even challenging psychedelic trips can be beneficial — especially within the context of mystical and insightful experiences. This finding in particular may be especially helpful for practitioners to know as they guide patients through clinical trials focusing on the therapeutic potential of psychedelics.

“Sometimes the challenge arises because it’s an intensely mystical and insightful experience that can, in and of itself, be challenging,” says senior study author Alan Davis, assistant professor and director of the Center for Psychedelic Drug Research and Education in The Ohio State University College of Social Work, in a media release.

Keep reading

Quebec Approves Magic Mushrooms Under Public Health Coverage

Quebec, Canada last week approved the used of psilocybin – the primary psychoactive in “magic mushrooms,” as a valid therapy under the state’s medical system.

Advocates hope the move will set a precedent for other Canadian provinces to take similar action, Forbes reports.

“This decision is a huge step forward for the use of psilocybin-assisted psychotherapy as a legitimate medical treatment,” wrote TheraPsil, a nonprofit group that advocates for the advancement of psilocybin therapies, in a Dec. 15 statement. “It not only provides greater access to this potentially life-changing treatment for patients in Quebec, but it also sets a precedent for other provinces to follow suit.”

Clinical research and other studies into psychedelics such as psilocybin have shown that the drugs have potential therapeutic benefits, particularly for serious mental health conditions such as depression, addiction and anxiety. Research published in the peer-reviewed journal JAMA Psychiatry in 2020 found that psilocybin-assisted psychotherapy was an effective and quick-acting treatment for a group of 24 participants with major depressive disorder. A separate study published in 2016 determined that psilocybin treatment produced substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. -Forbes

As we noted in April, psychedelic mushrooms are becoming increasingly popular in the US as a possible treatment for psychiatric disorders, with their main active ingredient, psilocybin, moving from the fringes of medicine, to become increasingly mainstream. It appears that Canada, however, is actually making moves to bring the benefits to actual patients.

Keep reading

TikTok’s algorithm promotes posts about eating disorders and suicide, report finds

TikTok’s algorithms are promoting videos about self-harm and eating disorders to vulnerable teens, according to a report published Wednesday that highlights concerns about social media and its impact on youth mental health.

Researchers at the nonprofit Center for Countering Digital Hate created TikTok accounts for fictional teen personas in the U.S., United Kingdom, Canada and Australia. The researchers operating the accounts then “liked” videos about self-harm and eating disorders to see how TikTok’s algorithm would respond.

Within minutes, the wildly popular platform was recommending videos about losing weight and self-harm, including ones featuring pictures of models and idealized body types, images of razor blades and discussions of suicide.

When the researchers created accounts with user names that suggested a particular vulnerability to eating disorders — names that included the words “lose weight” for example — the accounts were fed even more harmful content.

Keep reading

Mental health and worship apps are found to be some of the most privacy invasive

Apps that deal with some of the most sensitive and personal data, such as that concerning a user’s mental health or religious activities, are said to rank among the worst privacy offenders.

This is the conclusion of a study conducted by the Mozilla Foundation, which singled out mental health and prayer apps as being prone to track and collect data revealing a person’s state of mind, feelings, and thoughts, and then “share” that for-profit via targeted advertising.

Mozilla’s team looked into 32 apps from this category, putting a “privacy not included” label on 29, and publishing the findings in a guide of the same name. 25 of these apps didn’t pass the foundations’ minimum security standards around password quality and handling of security updates.

PTSD Coach, developed by the US The Department of Veterans Affairs, has “strong privacy policies and security practices,” while chatbot Wysa “seems to value users’ privacy.” And the Catholic prayer app Hallow was the only one to “respond in a timely manner” to Mozilla’s emails.

Besides these technical issues, the apps singled out in the report are also said to target “vulnerable users with personalized advertisements” and track and share biometric data.

Keep reading

Love & Other Drugs: The Couples Using Psychedelics as a Way To Get Closer

Some couples like to take time off and wander the world to recharge, rejuvenate and reconnect with each other. Others prefer a different kind of trip. 

Psychedelics are increasingly gaining prominence as well as regulatory approval as a form of treatment for mental health disorders ranging from PTSD to anxiety. This has also sparked a larger conversation on whether using hallucinogens like psilocybin mushrooms or LSD could then also emerge as a form of relationship therapy, given that these substances have the ability to curb inhibitions and change the way we perceive reality. 

The rise and rise of psychedelic wellness has also led to couples experimenting with the substances together, either to forge stronger bonds, deal with deep-seated issues in a controlled setting or simply share the euphoric experience together. In fact, though psychedelics are not legal in most countries, relationship counsellors are increasingly advocating their use in counselling sessions, where a couple is administered a mild dosage in a controlled environment, asked leading questions about their hopes and fantasies while they’re tripping, and given calculated counselling based on their experiences. 

“Psilocybin has incredible [potential] as a catalyst for such therapy because it tears down all your walls and filters, and changes the way you think about the relationship,” Kripi Malviya, a psychologist and founder of de-addiction and rehabilitation centre TATVA, told VICE. 

Keep reading

The Emerging Magic Mushroom Monopoly

In December 2017, one of the godfathers of the contemporary psychedelic renaissance, Bob Jesse, penned a manifesto for the commercial era of hallucinogens, one that echoed as far and wide as when Timothy Leary famously evangelized, “Turn on, tune in, drop out,” in 1966. Jesse delivered a very different kind of message: “Open science for all!”

A philanthropist and independent researcher, Jesse was instrumental to reviving a new wave of medical interest into psychedelic-assisted therapy starting in the 1990s. This new form of therapy offers a revolutionary approach to treating the rising cases of depression and anxiety in the U.S. But Jesse began to see this pioneering research pillaged by Big Pharma, as soon as it showed commercial value as a breakthrough treatment for mental illness.

In the manifesto, Jesse took a stand against would-be monopolists for flagrantly misusing patent laws, advocating instead for a shared creative commons for psychedelic research, with limited intellectual-property rights. The statement attracted over 100 co-signers, including every major figure in the psychedelic research and NGO community, from philanthropic funders to grassroots advocates.

But there was a notable absence from the list: the founders of Compass Pathways, a rapidly growing psychedelic therapy company bankrolled by major investors, notably Peter Thiel, the PayPal co-founder and right-wing political financier.

“It was very suspicious when they didn’t sign on to the letter. It gave a lot of people pause about what their plans were,” said Carey Turnbull, a longtime philanthropist in the psychedelic community who has become one of Compass Pathways’ main detractors.

Compass’s founders—millionaire couple George Goldsmith and Ekaterina Malievskaia—had already raised eyebrows by quietly transitioning from a charity organization to a for-profit corporation in 2017. Compass was also conducting dubious drug trials on the Isle of Man, an infamous tax haven for the uber-wealthy with lax regulatory oversight. Suspicions abounded about the unusually restrictive contracts it pushed researchers to sign, and reports that Compass had blocked other organizations from signing a deal with one of their drug manufacturers.

The unwillingness to sign the letter was more than a snub. It was a harbinger of things to come.

Keep reading

Hallucinogen in ‘magic mushrooms’ relieves depression in largest clinical trial to date

Psilocybin, the hallucinogen found in “magic mushrooms,” helped to relieve symptoms in people with hard-to-treat depression in the largest clinical trial of its kind to date, the trial’s organizers announced Tuesday (Nov. 9).

Earlier this year, a small study suggested that psilocybin might work as well as the common antidepressant escitalopram (Lexapro) at relieving moderate to severe depression, and other past research has hinted at the drug’s promise, Live Science previously reported. But this new trial, conducted by the pharmaceutical company Compass Pathways, is the largest gold-standard trial of psilocybin to date, so its results could carry more weight than previous research, STAT reported. 

Keep reading